Evaluating the Association Between Pericardial Fat & Coronary Heart

Status Completed

Clinical Trial Summary

Coronary heart disease (CHD) is the leading cause of death in the United States. One common risk factor for CHD is obesity. The presence of certain types of fat over others is more commonly associated with the development of CHD. This study will use data from a previous study to examine the association between pericardial fat, a type of fat that surrounds the heart, and CHD.

Clinical Trial Description

CHD is caused by a narrowing of the small blood vessels that supply blood and oxygen to the heart. It usually results from atherosclerosis, a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries. Risk factors for CHD include tobacco use, high blood pressure, diabetes, and obesity. Visceral fat, the type of fat found in the abdomen and surrounding vital organs, is considered a greater risk factor for CHD than subcutaneous fat, the type of fat found directly below the skin. Pericardial fat, the fat surrounding the heart, is similar to visceral fat, and may be particularly damaging because of its lipotoxicity effects and its ability to trigger inflammation in the coronary arteries. Increased amounts of pericardial fat may therefore accelerate the development of atherosclerosis and CHD. The purpose of this study is to evaluate the relationship between pericardial fat and the development of CHD.

This study will use previously collected data from participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study, a study that examined characteristics of the subclinical, or the early stages of, cardiovascular disease in individuals. There will be no study visits specifically for this study. Participants' study data and computed tomography (CT) scans will be analyzed to determine the following: 1) the presence of pericardial fat and subclinical CHD at study entry; 2) changes in pericardial fat levels and plaque formation; and 3) the presence of pericardial fat and CHD at a 6-year follow-up visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00402922
Study type	Observational
Source	Wake Forest University Health Sciences
Contact
Status	Completed
Phase	N/A
Start date	August 2006
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Completed	`NCT05672862` - International Post-PCI FFR Extended Registry
Completed	`NCT04492423` - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed	`NCT00046410` - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Not yet recruiting	`NCT02895009` - Hemostatic Compression Patterns After Transradial Coronary Intervention	N/A
Completed	`NCT02784873` - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes	N/A
Completed	`NCT02948517` - Time Restricted Feeding for Weight Loss and Cardio-protection	N/A
Recruiting	`NCT02859480` - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI	Phase 4
Withdrawn	`NCT02418143` - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Completed	`NCT02382731` - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction	N/A
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Completed	`NCT02248415` - Administration of Warm Blood Cardioplegia With or Without Roller Pump	N/A
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Completed	`NCT02088138` - Functional Electrical Stimulation in Cardiac Patients	N/A
Completed	`NCT02173067` - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective	N/A
Completed	`NCT02133807` - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluating the Association Between Pericardial Fat and Coronary Heart Disease - Ancillary to MESA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms